查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771293

KRAS市场:产业趋势和全球预测 - 各适应症，各分子类型，治疗类别，各给药途径，主要各地区

KRAS Market: Industry Trends and Global Forecasts - Distribution by Type of Indication, Type of Molecule, Type of Therapy, Route of Administration and Key Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 131 Pages | 商品交期: 最快1-2个工作天内

价格

全球 KRAS 市场：概览

今年全球 KRAS 市场规模达 7,300 万美元。预计预测期内，该市场的复合年增长率将达到 53.6%。

市场区隔与机会分析依下列参数细分：

适应症类型

  • 急性骨髓性白血病
  • 大肠癌症
  • 头颈椎癌症
  • 肺癌症
  • 卵巢癌症
  • 胰臟癌症
  • Phelan-McDermid 症候群
  • 皮肤癌症

分子类型

  • 生物製药
  • 低分子

治疗类型

  • 单剂疗法
  • 联合治疗

给药途径

  • 静脉注射
  • 肌肉内给药
  • 皮内
  • 眼内
  • 腹腔内
  • 口服
  • 皮下

主要地区

  • 北美
  • 欧洲
  • 亚太地区
  • 中东·北非
  • 南美

全球KRA市场：成长与趋势

癌症是心血管疾病后的第二大死因，占全球已通报死亡人数的六分之一。根据国际癌症研究机构 (IARC) 的数据，预计到 2040 年，全球新增癌症病例将增加至 2,750 万人。癌症高死亡率的主要原因是诊断往往延误，从而导致治疗延误，大大降低了患者的生存机会。

KRAS Market-IMG1

由于传统疗法在治疗RAS突变癌症方面未能显示出显着疗效，专门针对RAS基因的新型药物已成为有希望的选择。事实上，该领域的药物开发者越来越专注于开发针对特定癌症基因突变的疗法，这些突变是疾病发生和进展的主要原因。值得注意的是，RAS曾被认为是无法治癒的靶点，但它与30%的人类癌症有关。多年来，许多专门针对RAS突变基因的候选药物已被研究。此外，在令人鼓舞的临床试验结果、大量资金投入以及对标靶治疗日益增长的需求的推动下，RAS靶向治疗市场预计将在未来十年稳步增长。

全球 KRAS 市场：关键洞察

本报告分析了全球 KRAS 市场的现状，并探讨了潜在的成长机会。报告的主要发现包括：

  • 目前，多家公司声称正在开髮用于治疗 RAS 突变引起的各种癌症的新型候选药物。
  • 大多数新型候选药物在开发早期阶段进行评估，并以单一药物或与其他产品合併使用，并透过各种给药途径给药。
  • 超过 70% 的治疗药物在临床前和临床阶段以单一药物或与其他产品合併使用的方式进行评估。大多数针对 RAS 的治疗药物 (79%) 设计为口服给药。
KRAS Market-IMG2
  • 为了获得竞争优势，各地区的公司都在积极投入资源和资金，用于研发自主研发的产品。
  • 近年来，各地区与此类新型疗法相关的临床试验数量显着增加。
  • 据报道，就註册试验数量而言，临床研究活动在过去三年中以 5% 的复合年增长率增长。在全部试验中，近 25% 已经完成，而 60% 仍在进行中并仍在招募患者。
  • 近年来，许多公司已经结成策略联盟，以开发新型小分子候选药物。
  • 大部分是产品授权协议，占总数的30%以上。
  • 过去五年，许多公私投资者希望获得丰厚回报，在多轮融资中投资了该公司。
  • 其中近6亿美元来自创投，约占总额的40%。同时，据报导有超过五家公司进行了IPO/上市，这些公司共筹集超过7.75亿美元。
  • 过去和正在进行的研究重点是癌症治疗。
  • 去年，隶属于认可大学的作者（80%）大多发表了以KRAS为重点的论文。
  • 过去几年，以RAS标靶治疗为重点的论文（包括研究论文）数量急剧增加。
  • 从已发表的论文/文章可以看出，目前的研究活动主要集中在针对RAS亚型，主要是突变的KRAS基因。
  • 大多数出版品关注的是针对大肠直肠癌、肺癌和胰臟癌的RAS标靶治疗。
  • 为了充分实现其独特产品的商业化，药物开发商正在产品上市週期的各个阶段积极探索各种商业化策略。
  • 受日益加重的癌症负担和对标靶药物治疗需求的推动，RAS标靶治疗市场预计将在未来十年呈现可观的成长率。
  • 预计整体市场机会将涵盖各种类型的治疗药物和给药途径。
KRAS Market-IMG3

KRAS市场参与企业案例

  • Amgen
  • GlobeImmune
  • Jacobio Pharmaceuticals
  • Mirati Therapeutics
  • Novartis
  • Onconova Therapeutics
  • Targovax
  • Verastem Oncology.

全球KRAS市场

    全球 KRAS 市场

    • 市场规模与机会分析：本报告对全球 KRAS 市场进行了详细分析，重点关注以下关键细分市场：[A] 适应症类型、[B] 分子类型、[C] 疗法类型、[D] 给药途径和 [E] 重点区域。
    • 市场模式：对 RAS 标靶疗法进行全面评估，考虑了 A] 开发现状、[B] 开发阶段、[C] 分子类型、[D] 疗法类型、[E] 目标治疗领域、[F] 目标基因、[G] 治疗线、[H] 给药途径等多项参数。此外，本报告还基于 [A] 成立年份、[B] 员工人数、[C] 地理位置等多项相关参数，对从事 RAS 标靶疗法开发的公司进行了全面评估。
    • 临床试验分析：基于多个相关参数，对各种 RAS 标靶疗法的临床试验进行详细分析，这些参数包括 A] 临床试验註册年份、[B] 临床试验阶段、[C] 临床试验招募状态、[D] 入组患者人群、[E] 试验设计、[F] 主要行业申办者/合作者、[G] 临床适应症、H临床试验的区域分布等。
    • 产品竞争分析：透过考虑 A] 公司规模、[B] 先导分子开发阶段等因素，对参与 KRAS 市场的主要公司进行深入的竞争分析（基于其各自开发产品组合的实力）。
    • 公司简介：提供 RAS 标靶疗法的公司的详细简介，重点关注 A] 公司概况、[B] 产品组合、[C] 最新发展和明智的未来展望。
    • 出版物分析：基于 A] 出版年份、[B] 重点领域、[C] 分子类型、[D] 热门关键字和 [E] 领先期刊，对约 1,600 篇与 RAS 标靶治疗研究相关的同行评审科学论文进行全面分析。
    • 合作关係与协作：基于 A] 合作年份、[B] 合作类型、[C] 分子类型、[D] 最活跃的参与者（已达成的合作伙伴关係数量）、[E] 合作活动的区域分布等多个参数，对该领域利益相关者达成的交易进行深入分析。
    • 资金与投资：对各种投资进行详细分析，例如 A] 创投、[B] 债务融资、[C] 拨款/奖励、[D] 首次公开发行 (IPO) 融资、[E] 服务于 KRAS 市场的参与者随后进行的公开发行 (IPO)。
    • 关键商业化策略：详细介绍 KRAS 市场药物开发商在市场发展的各个阶段（包括上市前、上市/上市中以及上市后）所采用的各种商业化策略。

    本报告概述了全球 KRAS 市场，关键细分领域包括适应症、分子类型、治疗类型、给药途径、区域趋势和公司概况。

    目录

    第1章 序文

    第2章 摘要整理

    第3章 简介

    • RAS 标靶治疗概述
    • 针对突变 RAS 基因的方法
    • 值得注意的历史发展
    • RAS 突变癌症中值得注意的基因驱动相关突变
    • RAS 突变癌症治疗的课题与未来前景

    第4章 目前的市场情势

    • RAS标靶治疗:开发平台评估
    • RAS标靶治疗:开发形势

    第5章 与临床试验端点分析

    • RAS标靶治疗:临床试验一览

    第6章 产品竞争力分析

    • 产品竞争力:北美
    • 产品竞争力:欧洲
    • 产品竞争力:亚太地区

    第7章 企业简介

    • Amgen
    • GlobeImmune
    • Jacobio Pharmaceuticals
    • Mirati Therapeutics
    • Novartis
    • Onconova Therapeutics
    • Targovax
    • Verastem Oncology

    第8章 出版物的分析

    • RAS标靶治疗:最近的出版物

    第9章 伙伴关係和合作

    • RAS标靶治疗:伙伴关係和合作的清单

    第10章 与资金筹措投资分析

    • RAS标靶治疗:资金筹措与投资

    第11章 主要商业化策略

    第12章 市场规模的评估与机会分析

    • 预测研究方法与关键假设
    • 2035年全球RAS标靶治疗市场
    • 2035年全球RAS标靶治疗市场（依适应症划分）
    • 2035年全球RAS标靶治疗市场（依分子类型划分）
    • 2035年全球RAS标靶治疗市场（依治疗类型划分）
    • 2035年全球RAS标靶治疗市场（依给药途径划分）
    • 2035年全球RAS标靶治疗市场（按地区划分）
    • RAS标靶治疗：单一产品销售预测
      • LUMAKRASTM（安进）：销售额预测
      • Adagrasib（Mirati Therapeutics）：销售额预测
      • AMO-01（AMO Pharma）：销售额预测
      • Antroquinonol (Golden Biotech): 销售预测
      • Binimetinib (Array Biopharma): 销售预测
      • CH7126766/VS6766 (Verastem Oncology): 销售预测
      • LXH274 (Novartis): 销售预测
      • Rigosertib (Onconova Therapeutics): 销售预测
      • RMC-4630 (Revolution Medicine): 销售预测
      • TG01 (Targovax): 销售预测
      • Tipifarnib (Kura Oncology): 销售预测
      • siG12D (Silenseed): 销售预测

    第13章 结论

    第14章 附录1:表格形式资料

    第15章 附录2:企业·团体一览

Product Code: RA100292

GLOBAL KRAS MARKET: OVERVIEW

As per Roots Analysis, the global KRAS market valued at USD 73 million in the current year is expected to grow at a CAGR of 53.6% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Indication

  • Acute Myeloid Leukemia
  • Colorectal Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Phelan-McDermid Syndrome
  • Skin Cancer

Type of Molecule

  • Biologic
  • Small Molecule

Type of Therapy

  • Monotherapy
  • Combination Therapy

Route of Administration

  • Intravenous
  • Intramuscular
  • Intradermal
  • Intraocular
  • Intraperitoneal
  • Oral
  • Subcutaneous

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa
  • Latin America

GLOBAL KRAS MARKET: GROWTH AND TRENDS

Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5 million across the globe, by 2040. A major factor contributing to the high mortality rate associated with this condition is the tendency for late diagnosis, which in turn delays treatment and significantly reduces the patient's chances of survival.

KRAS Market - IMG1

Given that conventional therapies have been unable to exhibit significant efficacy in the treatment of RAS mutated cancers, novel drugs, specifically targeting the RAS gene, have emerged as a promising alternative. In fact, drug developers in this field are increasingly focusing on creating therapies that target specific oncogenic mutations primarily responsible for the onset and progression of the disease. Notably, RAS which was once considered to be an undruggable target, has been linked to 30% of human cancer. Over the years, numerous drug candidates have been investigated to specifically target RAS-mutated genes. Additionally, driven by encouraging clinical trial results, substantial financial assistance, and growing demand for targeted therapeutic modalities, the RAS targeting therapies market is anticipated to witness steady growth over the next decade

GLOBAL KRAS MARKET: KEY INSIGHTS

The report delves into the current state of global KRAS market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Presently, several companies claim to be engaged in the development of novel drug candidates for the treatment of various cancers originating due to RAS mutations.
  • Most of the drug candidates are being evaluated in early stages of development, either as monotherapies or in combination with other products, for delivery via different administration routes.
  • Over 70% of the therapies are being evaluated across preclinical and clinical stages, either as monotherapies or in combination with other products. Majority of the RAS targeting therapies (79%) are designed for administration via the oral route.
KRAS Market - IMG2
  • In pursuit of gaining a competitive edge, firms located in different regions are actively investing, in terms of both resources and capital, to conduct R&D of their proprietary products.
  • Over the years, there has been significant increase in number of clinical trials related to this novel class of therapies, across different geographies.
  • Clinical research activity, in terms of the number of trials registered, is reported to have increased at a CAGR of 5%, in the past three years. Of the total number of trials, close to 25% of the studies have already been completed, while 60% are active and still recruiting patients.
  • In recent years, a large number of companies have recently entered into strategic collaborations for the development of novel small molecule candidates.
  • Majority of the deals were reported to be product licensing agreements, representing over 30% of the total number of instances.
  • Foreseeing lucrative returns, many public and private investors have made investments across several funding rounds, in the last five years.
  • Of the total, close to USD 600 million was raised through venture capital financing, representing around 40% of the overall share. On the other hand, over 5 instances of IPOs / secondary offerings were reported, wherein players collectively raised more than USD 775 million in financing.
  • Both industry players and academic institutes have made significant contributions towards expanding the pool of published scientific literature; past and ongoing studies were focused on treatment of cancer indications.
  • Majority of the authors affiliated with deemed universities have published articles focused on KRAS (80%), in the last year.
  • In the past years, there has been an exponential increase in the number of publications, including research articles focused on RAS targeting therapies.
  • Published articles / papers indicate that the current research activity is focused on targeting RAS isoforms, primarily mutated KRAS gene.
  • Majority of the publications are focused on RAS targeting therapies intended for colorectal cancer, lung cancer and pancreatic cancer.
  • In order to adequately monetize their proprietary offerings, drug developers are actively exploring diverse commercialization strategies across various stages of a product's launch cycle.
  • Driven by the growing cancer burden and rising need for targeted drug therapies, the RAS targeted therapies market is projected to grow at a lucrative rate over the coming decade.
  • The overall market opportunity is likely to be distributed across different types of therapies and routes of administration.
KRAS Market - IMG3

Example Players in the KRAS Market

  • Amgen
  • GlobeImmune
  • Jacobio Pharmaceuticals
  • Mirati Therapeutics
  • Novartis
  • Onconova Therapeutics
  • Targovax
  • Verastem Oncology.

GLOBAL KRAS MARKET

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global KRAS market, focusing on key market segments, including [A] type of indication, [B] type of molecule, [C] type of therapy, [D] route of administration and [E] key geographical regions.
  • Market Landscape: A comprehensive evaluation of RAS targeting therapies, considering various parameters, such as [A] current status of development, [B] phase of development, [C] type of molecule, [D] type of therapy, [E] target therapeutic area, [F] target gene, [G] line of treatment and [H] route of administration. Additionally, the section includes a comprehensive evaluation of companies engaged in the development of RAS targeting therapies, based on several relevant parameters, such as [A] year of establishment, [B] employee count and [C] geographical presence.
  • Clinical Trial Analysis: An in-depth analysis of clinical trials of various RAS targeting therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial phase, [C] trial recruitment status, [D] enrolled patient population, [E] study design, [F] leading industry sponsors / collaborators, [G] trial focus, [H] target indication, [I] most popular indications and [J] regional distribution of trials.
  • Product Competitiveness Analysis: An insightful competitive analysis of key players engaged in KRAS market (on the basis of the strength of their respective development portfolios), examining factors, such as [A] company size and [B] stage of development of lead molecules.
  • Company Profiles: In-depth profiles of companies engaged in offering RAS targeting therapies, focusing on [A] company overview, [B] product portfolio and [C] recent developments and an informed future outlook.
  • Publication Analysis: A comprehensive analysis of close to 1,600 peer-reviewed scientific articles related to research on RAS targeting therapies, based on [A] year of publication, [B] focus areas, [C] type of molecule, [D] popular keywords and [E] key journals.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in this domain, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of molecule, [D] most active players (in terms of the number of partnerships signed) and [E] geographical distribution of partnership activity.
  • Funding and Investments: An in-depth analysis of various investments, such as [A] venture capital financing, [B] debt financing, [C] grants / awards, [D] capital raised from IPOs and [E] subsequent offerings that were undertaken by players engaged in KRAS market.
  • Key Commercialization Strategies: A detailed discussion on the various commercialization strategies that have been adopted by drug developers engaged in KRAS market across different stages of therapy development, including pre-drug launch, at / during drug launch and post-marketing stage.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Overview of RAS Targeting Therapies
  • 3.2. Approaches Used to Target Mutated RAS Gene
  • 3.3. Historical Notable Developments
  • 3.4. Prominent Gene Driver Related Mutations in RAS Mutated Cancers
  • 3.5. Challenges and Future Perspectives Associated with Treatment of RAS Mutated Cancers

4. CURRENT MARKET LANDSCAPE

  • 4.1. RAS Targeting Therapies: Pipeline Review
    • 4.1.1. Analysis by Phase of Development
    • 4.1.2. Analysis by Route of Administration
    • 4.1.3. Analysis by Line of Treatment
    • 4.1.4. Analysis by Type of Therapy
    • 4.1.5. Analysis by Type of Molecule
    • 4.1.6. Analysis by Target Gene
    • 4.1.7. Analysis by Target Therapeutic Area
    • 4.1.8. Analysis by Phase of Development and Leading Players
  • 4.2. RAS Targeting Therapies: Developer Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Geography

5. CLINICAL TRIALS AND ENDPOINT ANALYSIS

  • 5.1. RAS Targeting Therapies: List of Clinical Trials
    • 5.1.1. Analysis by Trial Status
    • 5.1.2. Analysis by Trial Registration Year
    • 5.1.3. Analysis by Type of Masking
    • 5.1.4. Analysis by Type of Intervention Model
    • 5.1.5. Analysis by Study Design
    • 5.1.6. Analysis by Type of Sponsor
    • 5.1.7. Most Active Players: Analysis by Number of Trials Registered
    • 5.1.8. Analysis by Trial Registration Year and Geography
    • 5.1.9. Analysis by Type of Target Indication
    • 5.1.10. Analysis by Enrolled Patient Population
    • 5.1.11. Analysis of Enrolled Patient Population by Geography
    • 5.1.12. Analysis of Number of Clinical Trials by Geography

6. PRODUCT COMPETITIVENESS ANALYSIS

  • 6.1. Product Competitiveness: North America
  • 6.2. Product Competitiveness: Europe
  • 6.3. Product Competitiveness: Asia-Pacific

7. COMPANY PROFILES

  • 7.1. Amgen
    • 7.1.1. Company Overview
    • 7.1.2. Financial Information
    • 7.1.3. Portfolio of RAS Targeting Therapies
    • 7.1.4. Recent Developments and Future Outlook
  • 7.2. GlobeImmune
    • 7.2.1. Company Overview
    • 7.2.2. Financial Information
    • 7.2.3. Portfolio of RAS Targeting Therapies
    • 7.2.4. Recent Developments and Future Outlook
  • 7.3. Jacobio Pharmaceuticals
    • 7.3.1. Company Overview
    • 7.3.2. Financial Information
    • 7.3.3. Portfolio of RAS Targeting Therapies
    • 7.3.4. Recent Developments and Future Outlook
  • 7.4. Mirati Therapeutics
    • 7.4.1. Company Overview
    • 7.4.2. Financial Information
    • 7.4.3. Portfolio of RAS Targeting Therapies
    • 7.4.4. Recent Developments and Future Outlook
  • 7.5. Novartis
    • 7.5.1. Company Overview
    • 7.5.2. Financial Information
    • 7.5.3. Portfolio of RAS Targeting Therapies
    • 7.5.4. Recent Developments and Future Outlook
  • 7.6. Onconova Therapeutics
    • 7.6.1. Company Overview
    • 7.6.2. Financial Information
    • 7.6.3. Portfolio of RAS Targeting Therapies
    • 7.6.4. Recent Developments and Future Outlook
  • 7.7. Targovax
    • 7.7.1. Company Overview
    • 7.7.2. Financial Information
    • 7.7.3. Portfolio of RAS Targeting Therapies
    • 7.7.4. Recent Developments and Future Outlook
  • 7.8. Verastem Oncology
    • 7.8.1. Company Overview
    • 7.8.2. Financial Information
    • 7.8.3. Portfolio of RAS Targeting Therapies
    • 7.8.4. Recent Developments and Future Outlook

8. PUBLICATION ANALYSIS

  • 8.1. RAS Targeting Therapies: Recent Publications
    • 8.1.1. Analysis by Year of Publication
    • 8.1.2. Analysis by Type of Publication
    • 8.1.3. Analysis by Study Objective
    • 8.1.4. Analysis by Emerging Focus Areas
    • 8.1.5. Analysis by Target Therapeutic Area
    • 8.1.6. Analysis by Target Gene
    • 8.1.7. Analysis by Target Indication
    • 8.1.8. Analysis by Affiliation of First Author
    • 8.1.9. Leading Players: Analysis by Number of Publications
    • 8.1.10. Key Journals: Analysis by Number of Publications

9. PARTNERHSIPS AND COLLABORATIONS

  • 9.1. RAS Targeting Therapies: List of Partnerships and Collaborations
    • 9.1.1. Analysis by Year of Partnership
    • 9.1.2. Analysis by Type of Partnership
    • 9.1.3. Analysis by Type of Partner
    • 9.1.4. Analysis by Type of Molecule
    • 9.1.5. Most Active Players: Analysis by Number of Partnerships
    • 9.1.6. Most Active Partners: Analysis by Number of Partnerships
    • 9.1.7. Regional Analysis
    • 9.1.8. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS

  • 10.1. RAS Targeting Therapies: Funding and Investments
    • 10.1.1. Analysis by Number of Funding Instances
    • 10.1.2. Analysis by Amount Invested
    • 10.1.3. Analysis by Type of Funding
    • 10.1.4. Most Active Players: Analysis by Amount Raised
    • 10.1.5. Most Active Investors: Analysis by Number of Instances
    • 10.1.6. Analysis by Geography

11. KEY COMMERCIALIZATION STRATEGIES

  • 11.1. Successful Drug Launch Strategy: ROOTS Framework
  • 11.2. Successful Drug Launch Strategy: Product Differentiation
  • 11.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
  • 11.4. Key Commercialization Strategies Adopted by Companies Focused on RAS Targeting Therapies
    • 11.4.1. Strategies Adopted Before Therapy Approval
  • 11.5. Strategies Adopted During / Post Therapy Approval
  • 11.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)

12. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 12.1. Forecast Methodology and Key Assumptions
  • 12.2. Global RAS Targeting Therapies Market, Till 2035
  • 12.3. Global RAS Targeting Therapies Market, Till 2035: Distribution by Target Indication
  • 12.4. Global RAS Targeting Therapies Market, Till 2035: Distribution by Type of Molecule
  • 12.5. Global RAS Targeting Therapies Market, Till 2035: Distribution by Type of Therapy
  • 12.6. Global RAS Targeting Therapies Market, Till 2035: Distribution by Route of Administration
  • 12.7. Global RAS Targeting Therapies Market, Till 2035: Distribution by Geography
  • 12.8. RAS Targeting Therapies: Individual Product Sales Forecasts
    • 12.8.1. LUMAKRASTM (Amgen): Sales Forecast
    • 12.8.2. Adagrasib (Mirati Therapeutics): Sales Forecast
    • 12.8.3. AMO-01 (AMO Pharma): Sales Forecast
    • 12.8.4. Antroquinonol (Golden Biotech): Sales Forecast
    • 12.8.5. Binimetinib (Array Biopharma): Sales Forecast
    • 12.8.6. CH7126766/VS6766 (Verastem Oncology): Sales Forecast
    • 12.8.7. LXH274 (Novartis): Sales Forecast
    • 12.8.8. Rigosertib (Onconova Therapeutics): Sales Forecast
    • 12.8.9. RMC-4630 (Revolution Medicine): Sales Forecast
    • 12.8.10. TG01 (Targovax): Sales Forecast
    • 12.8.11. Tipifarnib (Kura Oncology): Sales Forecast
    • 12.8.12. siG12D (Silenseed): Sales Forecast

13. CONCLUSION

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 4.1 RAS Targeting Therapies: List of Industry and Non-Industry Players
  • Table 5.1 RAS Targeting Therapies: List of Clinical Trials
  • Table 8.1 RAS Targeting Therapies: List of Recent Publications
  • Table 9.1 RAS Targeting Therapies: List of Partnerships and Collaborations
  • Table 10.1 RAS Targeting Therapies: List of Funding and Investments
  • Table 14.1 RAS Targeting Therapies: Distribution by Phase of Development
  • Table 14.2 RAS Targeting Therapies: Distribution by Route of Administration
  • Table 14.3 RAS Targeting Therapies: Distribution by Line of Treatment and Type of Therapy
  • Table 14.4 RAS Targeting Therapies: Distribution by Type of Molecule
  • Table 14.5 RAS Targeting Therapies: Distribution by Phase of Development and Type of Molecule
  • Table 14.6 RAS Targeting Therapies: Distribution by Type of Molecule and Route of Administration
  • Table 14.7 RAS Targeting Therapies: Distribution by Target Gene and Target Indication
  • Table 14.8 Most Active Players: Distribution by Number of Trials Registered
  • Table 14.9 RAS Targeting Therapy Developers: Distribution by Year of Establishment
  • Table 14.10 RAS Targeting Therapy Developers: Distribution by Company Size
  • Table 14.11 RAS Targeting Therapy Developers: Distribution by Location of Headquarters
  • Table 14.12 RAS Targeting Therapy Developers: Distribution by Geography
  • Table 14.13 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
  • Table 14.14 Clinical Trial Analysis: Distribution by Type of Masking and Intervention Model Adopted
  • Table 14.15 Clinical Trial Analysis: Distribution by Study Design and Trial Status
  • Table 14.16 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 14.17 Most Active Players: Distribution by Number of Clinical Trials
  • Table 14.18 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
  • Table 14.19 Clinical Trial Analysis: Distribution by Target Indication
  • Table 14.20 Clinical Trial Analysis: Distribution of Number of Trials by Geography
  • Table 14.21 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patients Population
  • Table 14.22 Clinical Trial Analysis: Distribution by Geography, Patients Enrolled and Trial Status
  • Table 14.23 Clinical Trial Analysis: Distribution by Patients Enrolled and Phase of Development
  • Table 14.24 Product Competitiveness Analysis: North America Scenario
  • Table 14.25 Product Competitiveness Analysis: Europe Scenario
  • Table 14.26 Product Competitiveness Analysis: Asia-Pacific Scenario
  • Table 14.27 Amgen: Financial Information
  • Table 14.28 GlobeImmune: Financial Information
  • Table 14.29 Jacobio Pharmaceuticals: Financial Information
  • Table 14.30 Mirati Therapeutics: Financial Information
  • Table 14.31 Novartis: Financial Information
  • Table 14.32 Onconova Therapeutics: Financial Information
  • Table 14.33 Targovax: Financial Information
  • Table 14.34 Verastem Oncology: Financial Information
  • Table 14.35 Publication Analysis: Distribution by Year of Publication
  • Table 14.36 Publication Analysis: Distribution by Type of Publication
  • Table 14.37 Publication Analysis: Distribution by Study Objective
  • Table 14.38 Publication Analysis: Distribution by Emerging Focus Area
  • Table 14.39 Publication Analysis: Distribution by Target Gene
  • Table 14.40 Publication Analysis: Distribution by Target Therapeutic Area
  • Table 14.41 Publication Analysis: Distribution by Target Indication
  • Table 14.42 Publication Analysis: Distribution by Affiliation of First Author
  • Table 14.43 Most Active Players: Distribution by Number of Publications
  • Table 14.44 Key Journals: Distribution by Number of Publications
  • Table 14.45 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 14.46 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 14.47 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 14.48 Partnerships and Collaborations: Distribution by Type of Molecule
  • Table 14.49 Most Active Players: Distribution by Number of Partnerships
  • Table 14.50 Most Active Partners: Distribution by Number of Partnerships
  • Table 14.51 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 14.52 Funding and Investment Analysis: Cumulative Year-wise Distribution by Amount Invested, Since 2016
  • Table 14.53 Funding and Investment Analysis: Distribution by Type of Funding
  • Table 14.54 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Table 14.55 Funding and Investment Analysis: Distribution by Year, Amount Invested and Type of Funding, Since 2016 (USD Million)
  • Table 14.56 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
  • Table 14.57 Key Investors: Distribution by Number of Funding Instances
  • Table 14.58 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
  • Table 14.59 Key Commercialization Strategies: Harvey Ball Analysis
  • Table 14.60 Successful Drug Launch Strategy: ROOTS Framework
  • Table 14.61 Historical Strategies Adopted by the Developer of LUMAKRAS(TM)
  • Table 14.62 Successful Drug Launch Strategy: Product Differentiation
  • Table 14.63 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
  • Table 14.64 Harvey Ball Analysis: Commercialization Strategies Adopted by RAS Targeting Therapy Developers
  • Table 14.65 RAS Targeting Therapies Market, Till 2035 (USD Million)
  • Table 14.66 RAS Targeting Therapies Market: Distribution by Type of Molecule / Drug Class (USD Million)
  • Table 14.67 RAS Targeting Therapies Market: Distribution by Type of Therapy (USD Million)
  • Table 14.68 RAS Targeting Therapies Market: Distribution by Route of Administration (USD Million)
  • Table 14.69 RAS Targeting Therapies Market: Distribution by Location of Headquarters (USD Million)
  • Table 14.70 LUMAKRAS(TM) (Amgen): Estimated Sales, Till 2035 (USD Million)
  • Table 14.71 Adagrasib (Mirati Therapeutics): Estimated Sales, Till 2035 (USD Million)
  • Table 14.72 AMO-01 (AMO Pharma): Estimated Sales, Till 2035 (USD Million)
  • Table 14.73 Antroquinonol (Golden Biotech): Estimated Sales, Till 2035 (USD Million)
  • Table 14.74 Binimetinib (Array Biopharma): Estimated Sales, Till 2035 (USD Million)
  • Table 14.75 CH7146766/VS6766 (Verastem Oncology): Estimated Sales, Till 2035 (USD Million)
  • Table 14.76 LXH274 (Novartis): Estimated Sales, Till 2035 (USD Million)
  • Table 14.77 Rigosertib (Onconova Therapeutics): Estimated Sales, Till 2035 (USD Million)
  • Table 14.78 RMC-4630 (Revolution Medicine): Estimated Sales, Till 2035 (USD Million)
  • Table 14.79 TG01 (Targovax): Estimated Sales, Till 2035 (USD Million)
  • Table 14.80 Tipifarnib (Kura Oncology): Estimated Sales, Till 2035 (USD Million)
  • Table 14.81 siG14D (Silenseed): Estimated Sales, Till 2035 (USD Million)
  • Table 14.82 RAS Targeting Therapies: Distribution by Target Therapeutic Area
  • Table 14.83 RAS Targeting Therapies: Distribution by Type of Molecule and Company Size
  • Table 14.84 RAS Targeting Therapies: Distribution by Company Size and Region
  • Table 14.85 Most Active Players: Distribution by Number of Products
  • Table 14.86 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 14.87 Clinical Trial Analysis: Distribution by Phase of Development, Year and Number of Patients
  • Table 14.88 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Region
  • Table 14.89 Clinical Trial Analysis: Distribution by Primary Purpose
  • Table 14.90 Funding and Investment Analysis: Cumulative Number of Funding Instances by Year, Since 2016
  • Table 14.91 Funding and Investment Analysis: Cumulative Amount Invested, Since 2016 (USD Million)
  • Table 14.92 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, Since 2016
  • Table 14.93 Funding and Investment Analysis: Distribution of Funding Instances by Geography
  • Table 14.94 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, Since 2016
  • Table 14.95 Most Active Players: Distribution by Number of Funding Instances, Since 2016
  • Table 14.96 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, Since 2016

List of Figures

  • Figure 3.1 Approaches for Targeting Mutated RAS Gene
  • Figure 3.2 Notable Developments within the RAS Targeting Therapies Domain
  • Figure 3.3 Prominent Gene Driver related Mutations in RAS Mutated Cancers
  • Figure 3.4 Key Challenges Associated with Targeting and Treatment of RAS Mutated Cancers
  • Figure 3.5 Future Perspectives of RAS Targeting Therapies
  • Figure 4.1 RAS Targeting Therapies: Distribution by Phase of Development
  • Figure 4.2 RAS Targeting Therapies: Distribution by Route of Administration
  • Figure 4.3 RAS Targeting Therapies: Distribution by Line of Treatment and Type of Therapy
  • Figure 4.4 RAS Targeting Therapies: Distribution by Type of Molecule
  • Figure 4.5 RAS Targeting Therapies: Distribution by Phase of Development and Type of Molecule
  • Figure 4.6 RAS Targeting Therapies: Distribution by Type of Molecule and Route of Administration
  • Figure 4.7 RAS Targeting Therapies: Distribution by Target Gene and Target Indication
  • Figure 4.8 Most Active Players: Distribution by Number of Trials Registered
  • Figure 4.9 RAS Targeting Therapy Developers: Distribution by Year of Establishment
  • Figure 4.10 RAS Targeting Therapy Developers: Distribution by Company Size
  • Figure 4.11 RAS Targeting Therapy Developers: Distribution by Location of Headquarters
  • Figure 4.12 RAS Targeting Therapy Developers: Distribution by Geography
  • Figure 5.1 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year
  • Figure 5.2 Clinical Trial Analysis: Distribution by Type of Masking and Intervention Model Adopted
  • Figure 5.3 Clinical Trial Analysis: Distribution by Study Design and Trial Status
  • Figure 5.4 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 5.5 Most Active Players: Distribution by Number of Clinical Trials
  • Figure 5.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
  • Figure 5.7 Clinical Trial Analysis: Distribution by Target Indication
  • Figure 5.8 Clinical Trial Analysis: Distribution of Number of Trials by Geography
  • Figure 5.9 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patients Population
  • Figure 5.10 Clinical Trial Analysis: Distribution by Geography, Patients Enrolled and Trial Status
  • Figure 5.11 Clinical Trial Analysis: Distribution by Patients Enrolled and Phase of Development
  • Figure 6.1 Product Competitiveness Analysis: North America Scenario
  • Figure 6.2 Product Competitiveness Analysis: Europe Scenario
  • Figure 6.3 Product Competitiveness Analysis: Asia-Pacific Scenario
  • Figure 7.1 Amgen: Financial Information
  • Figure 7.2 GlobeImmune: Financial Information
  • Figure 7.3 Jacobio Pharmaceuticals: Financial Information
  • Figure 7.4 Mirati Therapeutics: Financial Information
  • Figure 7.5 Novartis: Financial Information
  • Figure 7.6 Onconova Therapeutics: Financial Information
  • Figure 7.7 Targovax: Financial Information
  • Figure 7.8 Verastem Oncology: Financial Information
  • Figure 8.1 Publication Analysis: Distribution by Year of Publication
  • Figure 8.2 Publication Analysis: Distribution by Type of Publication
  • Figure 8.3 Publication Analysis: Distribution by Study Objective
  • Figure 8.4 Publication Analysis: Distribution by Emerging Focus Area
  • Figure 8.5 Publication Analysis: Distribution by Target Gene
  • Figure 8.6 Publication Analysis: Distribution by Target Therapeutic Area
  • Figure 8.7 Publication Analysis: Distribution by Target Indication
  • Figure 8.8 Publication Analysis: Distribution by Affiliation of First Author
  • Figure 8.9 Most Active Players: Distribution by Number of Publications
  • Figure 8.10 Key Journals: Distribution by Number of Publications
  • Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 9.4 Partnerships and Collaborations: Distribution by Type of Molecule
  • Figure 9.5 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.6 Most Active Partners: Distribution by Number of Partnerships
  • Figure 9.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 10.1 Funding and Investment Analysis: Cumulative Year-wise Distribution by Amount Invested, Since 2016
  • Figure 10.2 Funding and Investment Analysis: Distribution by Type of Funding
  • Figure 10.3 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Figure 10.4 Funding and Investment Analysis: Distribution by Year, Amount Invested and Type of Funding, Since 2016 (USD Million)
  • Figure 10.5 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
  • Figure 10.6 Key Investors: Distribution by Number of Funding Instances
  • Figure 10.7 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
  • Figure 11.1 Key Commercialization Strategies: Harvey Ball Analysis
  • Figure 11.2 Successful Drug Launch Strategy: ROOTS Framework
  • Figure 11.3 Historical Strategies Adopted by the Developer of LUMAKRAS(TM)
  • Figure 11.4 Successful Drug Launch Strategy: Product Differentiation
  • Figure 11.5 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
  • Figure 11.6 Harvey Ball Analysis: Commercialization Strategies Adopted by RAS Targeting Therapy Developers
  • Figure 12.1 RAS Targeting Therapies Market, Till 2035 (USD Million)
  • Figure 12.2 RAS Targeting Therapies Market: Distribution by Type of Molecule / Drug Class (USD Million)
  • Figure 12.3 RAS Targeting Therapies Market: Distribution by Type of Therapy (USD Million)
  • Figure 12.4 RAS Targeting Therapies Market: Distribution by Route of Administration (USD Million)
  • Figure 12.5 RAS Targeting Therapies Market: Distribution by Location of Headquarters (USD Million)
  • Figure 12.6 LUMAKRAS(TM) (Amgen): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.7 Adagrasib (Mirati Therapeutics): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.8 AMO-01 (AMO Pharma): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.9 Antroquinonol (Golden Biotech): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.10 Binimetinib (Array Biopharma): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.11 CH7126766/VS6766 (Verastem Oncology): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.12 LXH274 (Novartis): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.13 Rigosertib (Onconova Therapeutics): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.14 RMC-4630 (Revolution Medicine): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.15 TG01 (Targovax): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.16 Tipifarnib (Kura Oncology): Estimated Sales, Till 2035 (USD Million)
  • Figure 12.17 siG12D (Silenseed): Estimated Sales, Till 2035 (USD Million)
  • Figure 13.1 RAS Targeting Therapies: Distribution by Target Therapeutic Area
  • Figure 13.2 RAS Targeting Therapies: Distribution by Type of Molecule and Company Size
  • Figure 13.3 RAS Targeting Therapies: Distribution by Company Size and Region
  • Figure 13.4 Most Active Players: Distribution by Number of Products
  • Figure 13.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 13.6 Clinical Trial Analysis: Distribution by Phase of Development, Year and Number of Patients
  • Figure 13.7 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Region
  • Figure 13.8 Clinical Trial Analysis: Distribution by Primary Purpose
  • Figure 13.9 Funding and Investment Analysis: Cumulative Number of Funding Instances by Year, Since 2016
  • Figure 13.10 Funding and Investment Analysis: Cumulative Amount Invested, Since 2016 (USD Million)
  • Figure 13.11 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, Since 2016
  • Figure 13.12 Funding and Investment Analysis: Distribution of Funding Instances by Geography
  • Figure 13.13 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding, Since 2016
  • Figure 13.14 Most Active Players: Distribution by Number of Funding Instances, Since 2016
  • Figure 13.15 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, Since 2016